Jazz Pharmaceuticals plc — Director's Dealing 2017

Dec 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2017-12-11

Reporting Person: ENRIGHT PATRICK G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-11	Ordinary Shares	M	4500	$46.83	Acquired	20839	Direct
2017-12-11	Ordinary Shares	M	4500	$81.76	Acquired	25339	Direct
2017-12-11	Ordinary Shares	S	800	$138.145	Disposed	24539	Direct
2017-12-11	Ordinary Shares	S	5358	$139.5616	Disposed	19181	Direct
2017-12-11	Ordinary Shares	S	2842	$140.4977	Disposed	16339	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-11	Non-Qualified Stock Option (right to buy)	$46.83	M	4500	Disposed	2022-08-08	Ordinary Shares (4500)	Direct
2017-12-11	Non-employee director stock option	$81.76	M	4500	Disposed	2023-08-07	Ordinary Shares (4500)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Includes 14,974 shares received as a pro rata liquidating distribution from Longitude Venture Partners, L.P. ("Longitude Venture") and Longitude Capital Associates, L.P. ("Longitude Capital") to their respective partners. In prior reports, the Reporting Person reported indirect ownership of the Issuer's securities held by Longitude Venture and Longitude Capital but disclaimed beneficial ownership except to the extent of his pecuniary interest therein. The Reporting Person is a managing member of Longitude Capital Partners, LLC, the general partner of each of Longitude Venture and Longitude Capital.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.8000 to $138.6800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $139.1000 to $140.0800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.1700 to $141.1000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F6: This non-qualified stock option was granted on August 9, 2012 and vested over a period of one year from the grant date. The options were fully vested as of August 9, 2013.

F7: This Security is a non-qualified stock option (right to buy).

F8: This non-qualified stock option was granted on August 8, 2013 and vested over a period of one year beginning on September 1, 2013. The options were fully vested as of August 1, 2014.